Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

PGXL and Silicon Biosystems Collaborate

Published: Friday, April 26, 2013
Last Updated: Friday, April 26, 2013
Bookmark and Share
Companies to offer clinical research services focused on oncology genomics.

PGXL Technologies and Silicon Biosystems, Inc. announced a collaborative partnership to make the highly regarded Silicon Biosystems DEPArray technology available through PGXL Technologies. The PGXL program will allow clinical researchers and pharma sponsors to obtain the level of data fidelity and resolution needed in cancer biomarker discovery and translational research.

“As the DEPArray technology has gained recognition in the marketplace for its unmatched ability to recover pure cells for molecular characterization, we have received significant interest in having the platform available on a fee-for-service basis,” said Bob Proulx, President and General Manager of Silicon Biosystems’ U.S. operations. “Last year we added a demonstration and training lab, but partnering with PGXL for CRO services will add a whole new dimension to our ability to reach and impact the market.”

The DEPArray technology has broad application in the study of the underlying causes of disease, disease progression and the basis of drug resistance and efficacy. Recent technology progress in the areas of DNA and RNA analysis have shown that the complexity of diseases, like cancer, will require the characterization and comparison of different types of samples at the single cell level. The DEPArray system provides single-cell sorting, and can deliver the cell purity needed for the stringent downstream applications, such as next-gen sequencing and RNA expression profiling.

“We partnered with PGXL because they bring highly complementary capabilities and expertise to the equation,” Proulx continued. “Their experience in molecular methods and operation of a CLIA laboratory make them an ideal service provider for our prospective clients interested in genomic heterogeneity and translational research.”

“PGXL Tech exists to bring to market technologies that advance personalized medicine,” said Dr. Roland Valdes, Jr., President of PGXL Laboratories. “Making the DEPArray available on a fee-for-service basis empowers researchers to work with a precision that will speed discovery.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos